+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Alzheimer's Disease Therapeutics and Diagnostic Market 2019-2027

  • ID: 4773769
  • Report
  • February 2020
  • Region: Global
  • 184 pages
  • Triton Market Research

FEATURED COMPANIES

  • Abbvie
  • Baxter
  • Cognoptix
  • GE Healthcare
  • Merck
  • Roche
  • MORE
MARKET OUTLOOK

The Alzheimer’s disease therapeutics and diagnostics market is expected to progress at a CAGR of 7.78% during the years 2019-2027.

The market is driven by the rise in the number of Alzheimer’s cases and the growing demand for personalized drugs and affordable diagnostics tests. However, the stringent regulations for the development of drugs and clinical trials are hindering the growth of the Alzheimer’s disease therapeutics and diagnostics market globally. The high cost of therapies used for the treatment of Alzheimer’s disease also contributes to the same. A key challenge in the growth of the global Alzheimer’s disease therapeutics and diagnostics market is the shortage of skilled medical practitioners across the developing countries. Also, the lack of awareness regarding new therapies that are used for the treatment of the Alzheimer’s disease acts as a significant growth challenge for the global Alzheimer’s disease therapeutics and diagnostics market over the forecast period.

REGIONAL OUTLOOK

Europe, Asia Pacific and North America and rest of the world are the regional segments of the global Alzheimer’s disease therapeutics and diagnostics market. Presently, it is the Asia Pacific region that is holding the reign globally. With the government investment in the R&D for drugs and diagnostic test, which is further supported by the increasing population and the large proportion of people aged above 65 years in the regions, the demand for personalized drugs is expected to witness a boom for the Alzheimer’s disease therapeutics and diagnostics market in this region.

The Alzheimer’s disease therapeutics and diagnostics market in Asia-Pacific is the fastest-growing market globally. The primary driver of the Alzheimer’s disease therapeutics and diagnostics market in China is the burgeoning rise in the population of the country, which is thereby increasing the aging population. This aging population is vulnerable to diseases like dementia, thus causing a rise in its prevalence across the country, mainly in the semi-urban and rural provinces. According to the Ministry of Health, China is one of the leading countries in terms of the number of individuals affected by dementia, which accounts for around 20% of the dementia cases globally.

COMPETITIVE OUTLOOK

Some of the major players that are engaged in the Alzheimer’s disease therapeutics and diagnostics market include Baxter, AbbVie, Cognoptix, AXON Neuroscience SE, Biogen, DiaGenic ASA, Sun Pharmaceutical Industries Ltd., Amarantus BioScience Holdings, Inc., Merck, Piramal Enterprises Ltd., Johnson & Johnson, Roche, Siemens Healthineers AG, and GE Healthcare.

DiaGenic ASA is a life sciences company engaged in the development and delivery of patient-friendly tests to diagnose of devastating diseases at early stages. The company is currently focused on the development of IVD biomarker products and is also active in identifying gene expression signatures in blood in the field of Alzheimer’s disease. MCItect and New ADtect are some of the products that are a part of the company’s product portfolio. New ADtect is used for detecting mild to moderate AD.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • Baxter
  • Cognoptix
  • GE Healthcare
  • Merck
  • Roche
  • MORE
1. Global Alzheimer’s Disease Therapeutics And Diagnostic Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Threats of Substitute Product
2.2.3. Bargaining Power of Buyer
2.2.4. Bargaining Power of Supplier
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Etymology
2.5. Parent Market Outlook
2.6. Strategic Buying Criteria Outlook
2.7. Investments Outlook
2.8. Key Findings
2.9. Industry Structure
2.9.1. Research And Development
2.9.2. Manufacturing
2.9.3. Raw Materials
2.9.4. End User
2.9.5. Wholesalers
2.10. Regulatory Framework
2.11. The United States And Europe Regulatory Agency
2.12. Alzheimer's Disease Etiology
2.13. Pipeline Outlook
2.14. Phases And Sternness of Alzheimer’s Disease
2.15. Market Drivers
2.15.1. Growth of the Alzheimer’s Disease
2.15.2. Growing Geriatric Population
2.15.3. Substantial Investments by Government in Research
2.16. Market Restraints
2.16.1. Stringent Government Regulations
2.16.2. The Treatment of Alzheimer’s Disease Costs Very High
2.17. Market Opportunities
2.17.1. In-Vitro Diagnostic Techniques Are A Boon to the Market
2.17.2. R&D Investment in the Personalized Medicines is Increasing
2.18. Market Challenges
2.18.1. Awareness is Less Concerning New Therapies in the Alzheimer’s Disease
2.18.2. Very Few Skilled Professionals Pertaining to the Treatment of Alzheimer’s Disease

3. Alzheimer’s Disease Therapeutics And Diagnostics Market Outlook - by Therapeutics And Diagnostics
3.1. Therapeutics
3.1.1. Therapeutics by Drugs
3.1.1.1. Marketed Drugs
3.1.1.2. Pipeline Drugs
3.1.2. Therapeutics by Disease Stage
3.1.2.1. Late Stage: Severe Ad
3.1.2.2. Early/Middle Stage: Mild to Moderate Ad
3.1.3. Prodromal Stage
3.1.4. Therapeutics by Generic And Branded
3.1.4.1. Branded
3.1.4.2. Generic
3.2. Diagnostic Type
3.2.1. Lumbar Puncture Test
3.2.2. Positron Emission Tomography
3.2.3. Electroencephalography
3.2.4. Magnetic Resonance Imaging
3.2.5. Computed Tomography
3.2.6. Other Diagnostics

4. Alzheimer’s Disease Therapeutics And Diagnostics Market – Regional Outlook
4.1. North America
4.1.1. Market by Therapeutics And Diagnostics
4.1.2. Country Analysis
4.1.2.1. The United States
4.1.2.2. Canada
4.2. Europe
4.2.1. Market by Therapeutics And Diagnostics
4.2.2. Country Analysis
4.2.2.1. The United Kingdom
4.2.2.2. France
4.2.2.3. Germany
4.2.2.4. Spain
4.2.2.5. Italy
4.2.2.6. Russia
4.2.2.7. Rest of Europe
4.3. Asia-Pacific
4.3.1. Market by Therapeutics And Diagnostics
4.3.2. Country Analysis
4.3.2.1. China
4.3.2.2. India
4.3.2.3. Japan
4.3.2.4. Australia And New Zealand
4.3.2.5. South Korea
4.3.2.6. Asean Countries
4.3.2.7. Rest of Asia-Pacific
4.4. Latin America
4.4.1. Market by Therapeutics And Diagnostics
4.4.2. Country Analysis
4.4.2.1. Brazil
4.4.2.2. Mexico
4.4.2.3. Rest of Latin America
4.5. Middle East And Africa
4.5.1. Market by Therapeutics And Diagnostics
4.5.2. Country Analysis
4.5.2.1. Saudi Arabia
4.5.2.2. Turkey
4.5.2.3. United Arab Emirates
4.5.2.4. South Africa
4.5.2.5. Rest of Middle East & Africa

5. Company Profiles
5.1. Abbvie
5.2. Amarantus Bioscience Holdings, Inc.
5.3. Axon Neuroscience Se
5.4. Baxter
5.5. Biogen
5.6. Cognoptix
5.7. Diagenic Asa
5.8. Roche
5.9. Ge Healthcare
5.10. Merck
5.11. Johnson & Johnson
5.12. Piramal Enterprises Ltd.
5.13. Siemens Healthineers Ag
5.14. Sun Pharmaceutical Industries Ltd.

6. Research Methodology & Scope
6.1. Research Scope & Deliverables
6.1.1. Objectives of Study
6.1.2. Scope of Study
6.2. Sources of Data
6.2.1. Primary Data Sources
6.2.2. Secondary Data Sources
6.3. Research Methodology
6.3.1. Evaluation of Proposed Market
6.3.2. Identification of Data Sources
6.3.3. Assessment of Market Determinants
6.3.4. Data Collection
6.3.5. Data Validation & Analysis

List of Tables
Table 1 Global Alzheimer’s Disease Therapeutics And Diagnostics Market by Geography 2019-2027 ($ Million)
Table 2 Global Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Table 3 Global Alzheimer’s Disease Therapeutics And Diagnostics Market in Therapeutics by Drugs 2019-2027 ($ Million)
Table 4 Global Alzheimer’s Disease Therapeutics And Diagnostics Market in Disease Stage by Drugs 2019-2027 ($ Million)
Table 5 Global Alzheimer’s Disease Therapeutics And Diagnostics Market in Therapeutics by Generic And Branded 2019-2027 ($ Million)
Table 6 Global Alzheimer’s Disease Diagnostics Market by Diagnostic Type 2019-2027 ($ Million)
Table 7 Global Alzheimer’s Disease Therapeutics And Diagnostics Market by Geography 2019-2027 ($ Million)
Table 8 North America Alzheimer’s Disease Therapeutics And Diagnostics Market by Therapeutics And Diagnostics 2019-2027 ($ Million)
Table 9 North America Alzheimer’s Disease Therapeutics And Diagnostics Market by Country 2019-2027 ($ Million)
Table 10 Europe Alzheimers Disease Therapeutics And Diagnostic Market by Therapeutics And Diagnostics 2019-2027 ($ Million)
Table 11 Europe Alzheimers Disease Therapeutics And Diagnostic Market by Country 2019-2027 ($ Million)
Table 12 Asia-Pacific Alzheimer’s Disease Therapeutics And Diagnostics Market by Therapeutics And Diagnostics 2019-2027 ($ Million)
Table 13 Asia-Pacific Alzheimer’s Disease Therapeutics And Diagnostics Market by Country 2019-2027 ($ Million)
Table 14 Latin America Alzheimer’s Disease Therapeutics And Diagnostics Market by Therapeutics And Diagnostics 2019-2027 ($ Million)
Table 15 Latin America Alzheimer’s Disease Therapeutics And Diagnostics Market by Country 2019-2027 ($ Million)
Table 16 Middle East And Africa Alzheimer’s Disease Therapeutics And Diagnostics Market by Therapeutics And Diagnostics 2019-2027 ($ Million)
Table 17 Middle East And Africa Alzheimer’s Disease Therapeutics And Diagnostics Market by Country 2019-2027 ($ Million)

List of Figures
Figure 1 Global Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 2 Investments in Alzheimer’s Disease Treatment
Figure 3 Alzheimer's Drugs in the Pipeline by Treatment Focus (Number of Drugs)
Figure 4 Global Alzheimer’s Disease Therapeutics And Diagnostics Market in Therapeutics 2019-2027 ($ Million)
Figure 5 Global Alzheimer’s Disease Therapeutics Market in Marketed Drugs 2019-2027 ($ Million)
Figure 6 Global Alzheimer’s Disease Therapeutics Market in Pipeline Drugs 2019-2027 ($ Million)
Figure 7 Global Alzheimer’s Disease Therapeutics Market in Late Stage: Severe Ad 2019-2027 ($ Million)
Figure 8 Global Alzheimer’s Disease Therapeutics Market in Early/Middle Stage: Mild to Moderate Ad 2019-2027 ($ Million)
Figure 9 Global Alzheimer’s Disease Therapeutics Market in Prodromal Stage 2019-2027 ($ Million)
Figure 10 Global Alzheimer’s Disease Therapeutics Market in Branded 2019-2027 ($ Million)
Figure 11 Global Alzheimer’s Disease Therapeutics Market in Generic 2019-2027 ($ Million)
Figure 12 Global Alzheimer’s Disease Therapeutics And Diagnostics Market in Diagnostic Type 2019-2027 ($ Million)
Figure 13 Global Alzheimer’s Disease Diagnostics Market in Lumbar Puncture Test 2019-2027 ($ Million)
Figure 14 Global Alzheimer’s Disease Diagnostics Market in Positron Emission Tomography 2019-2027 ($ Million)
Figure 15 Global Alzheimer’s Disease Diagnostics Market in Electroencephalography 2019-2027 ($ Million)
Figure 16 Global Alzheimer’s Disease Diagnostics Market in Magnetic Resonance Imaging 2019-2027 ($ Million)
Figure 17 Global Alzheimer’s Disease Diagnostics Market in Computed Tomography 2019-2027 ($ Million)
Figure 18 Global Alzheimer’s Disease Diagnostics Market in Other Diagnostics 2019-2027 ($ Million)
Figure 19 The United States Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 20 Canada Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 21 Europe Alzheimers Disease Therapeutics And Diagnostic Market 2019-2027 ($ Million)
Figure 22 The United Kingdom Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 23 France Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 24 Germany Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 25 Spain Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 26 Italy Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 27 Russia Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 28 Rest of Europe Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 29 Asia-Pacific Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 30 China Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 31 India Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 32 Japan Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 33 Australia And New Zealand Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 34 South Korea Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 35 Asean Countries Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 36 Rest of Asia-Pacific Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 37 Latin America Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 38 Brazil Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 39 Mexico Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 40 Rest of Latin America Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 41 Middle East And Africa Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 42 Saudi Arabia Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 43 Turkey Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 44 United Arab Emirates Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 45 South Africa Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Figure 46 Rest of Middle East & Africa Alzheimer’s Disease Therapeutics And Diagnostics Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
  • Abbvie
  • Amarantus Bioscience Holdings, Inc.
  • Axon Neuroscience SE
  • Baxter
  • Biogen
  • Cognoptix
  • Diagenic ASA
  • Roche
  • GE Healthcare
  • Merck
  • Johnson & Johnson
  • Piramal Enterprises Ltd.
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll